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STUDY DESIGN: Systematic review and meta-analysis.
OBJECTIVE: To determine the difference in cardiovascular risk factors (blood pressure, lipid profile, and markers of glucose
metabolism and inflammation) according to the neurological level of spinal cord injury (SCI).
METHODS: We searched 5 electronic databases from inception until July 4, 2020. Data were extracted by two independent
reviewers using a pre-defined data collection form. The pooled effect estimate was computed using random-effects models, and
heterogeneity was calculated using I2 statistic and chi-squared test (CRD42020166162).
RESULTS: We screened 4863 abstracts, of which 47 studies with 3878 participants (3280 males, 526 females, 72 sex unknown)
were included in the meta-analysis. Compared to paraplegia, individuals with tetraplegia had lower systolic and diastolic blood
pressure (unadjusted weighted mean difference, −14.5 mmHg, 95% CI −19.2, −9.9; −7.0 mmHg 95% CI −9.2, −4.8, respectively),
lower triglycerides (−10.9 mg/dL, 95% CI −19.7, −2.1), total cholesterol (−9.9 mg/dL, 95% CI −14.5, −5.4), high-density lipoprotein
(−1.7 mg/dL, 95% CI −3.3, −0.2) and low-density lipoprotein (−5.8 mg/dL, 95% CI −9.0, −2.5). Comparing individuals with high-
vs. low-thoracic SCI, persons with higher injury had lower systolic and diastolic blood pressure (−10.3 mmHg, 95% CI −13.4, −7.1;
−5.3 mmHg 95% CI −7.5, −3.2, respectively), while no differences were found for low-density lipoprotein, serum glucose, insulin,
and inflammation markers. High heterogeneity was partially explained by age, prevalent cardiovascular diseases and medication
use, body mass index, sample size, and quality of studies.
CONCLUSION: In SCI individuals, the level of injury may be an additional non-modifiable cardiovascular risk factor. Future well-
designed longitudinal studies with sufficient follow-up and providing sex-stratified analyses should confirm our findings and
explore the role of SCI level in cardiovascular health and overall prognosis and survival.
Spinal Cord; https://doi.org/10.1038/s41393-021-00678-6
INTRODUCTION
Individuals with spinal cord injury (SCI) are known to have a higher
metabolic and cardiovascular disease (CVD) risk in comparison to
able-bodied individuals (ABI) due to changes in metabolism, body
morphology, and relative inactivity following the injury [1–3].
Long-term studies have shown that cardiovascular-related mor-
tality is higher compared to the general population and that CVDs
are one of the leading causes of death in individuals with traumatic
and non-traumatic SCI [4]. Using the data from the general
population, cohort studies have identified several non-modifiable
(e.g., sex, age, genetic predisposition, etc.) and modifiable (e.g.,
blood pressure, serum lipid profile, glucose levels, etc.) determi-
nants of increased cardiovascular risk [5]. CVD risk prediction
scoring systems such as Framingham risk score (FRS) or the HEART
score have been developed combining known CVD risk determi-
nants, and these scores are widely used for risk stratification in the
general population [6, 7]. However, the determinants of increased
CVD risk in SCI have not been fully elucidated, and the use of such
prediction models in SCI have been rarely studied in the literature
[8–10]. FRS may underestimate the CVD disease risk in people with
SCI [8–10] as this scoring system does not include SCI-specific risk
factors. The level of injury may be an additional non-modifiable
factor that may aggravate CVD risk and, therefore, a potential
factor to consider in the development of SCI-specific CVD risk
screening tools.
Biologically, the level of injury could significantly affect the
disability and functioning of an individual, which determines
mobility and baseline activity [11]. Depending on the injury level,
autonomic control, and metabolism of hormones, glucose, lipid,
and catecholamine could be impaired additionally [2, 3, 12].
Despite numerous attempts to determine the association between
the anatomic level of the injury and CVD risk factors, the majority
of studies were insufficiently powered to capture the changes in
CVD risk factors according to injury level [13–15]. Previous
narrative reviews had limited methodological quality and previous
systematic reviews focused on blood lipids and blood pressure
only [12, 16, 17]. Thus, the evidence on the influence of injury level
and CVD risk factors is still limited.
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In this review, we aim to summarize the available evidence on
the differences of modifiable cardiovascular risk factors according
to SCI level and explore further how completeness and injury
duration may affect this association. In addition, we aim to identify
the current literature gaps and provide directions for future
research.
METHODS
Data sources and search strategy
The current review was conducted following a recently published
guideline on how to perform systematic reviews and meta-
analysis in medical research and reported according to the
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) checklist [18]. The protocol was registered in the
PROSPERO Database (Registration number CRD42020166162).
An experienced information specialist searched four biblio-
graphic databases: MEDLINE (National Library of Medicine, US),
EMBASE (Elsevier, Netherlands), Web of Science (Clarivate
Analytics, US), and Cochrane (Cochrane Collaboration, UK) from
inception until July 4, 2020 (date last searched). In addition, we
downloaded the first 400 results from Google Scholar. The search
strategy combined terms related to (i) spinal cord injury such as
“spinal cord injury,” “paraplegia,” “quadriplegia,” etc., and (ii) CVD
risk factors (e.g., lipoproteins, inflammation markers, etc.) and was
filtered to include human studies only. Further, the reference lists
of the included studies and relevant reviews were searched for
eligible studies. Details of the search strategy are provided in the
Appendix.
Study selection and eligibility criteria
We limited our search to observational studies conducted in
adult (≥18 years old) humans with SCI. In particular, observational
studies were eligible for inclusion if they provided information on
any of the following CVD risk factors; blood pressure, glucose
metabolism, serum lipids, inflammation markers, coagulation
system/fibrinolysis markers, homocysteine, markers of oxidative
stress, markers of endothelial dysfunction and vascular function
and carotid atherosclerosis, disaggregated by different levels of
SCI. We excluded studies without comparison groups (e.g.,
studies focusing solely on individuals with paraplegia), animal
and in-vitro studies, reviews, commentaries, case studies, letters
to the editor, and conference abstracts. We used no language
restrictions.
Two authors screened titles and abstracts using the inclusion
and exclusion criteria mentioned above. Afterwards, the full texts
of the identified articles were reviewed independently by two
authors. Disagreements on the decision for inclusion were
discussed between the authors, and if consensus was not reached,
a third author was called to adjudicate the decision. Reasons for
exclusion of articles that underwent full-text reviews were
tabulated.
Data extraction
We used a predesigned data collection form to collect relevant
information from identified articles. To ensure the accuracy of data
extraction, two authors independently extracted the data from
identified articles. For variables/outcomes expressed in SI (Sys-
tème Internationale), we converted the data, using the standard
conversion tables (US National Institute of Standards and
Measures), to conventional units. In studies where median and
ranges (interquartile range, minimum-maximum values, crude
range) were reported, we converted the figures into mean and
standard deviation. Outcomes were collected according to
different injury levels. For cases of multiple publications, the most
recent information or the publication with the most relevant
outcome was used for the data extraction.
Risk of bias assessment
Methodological quality was assessed independently by two
independent authors using the Newcastle-Ottawa Scale (NOS)
for case-control, cross-sectional, or cohort studies, as applicable to
the study [19]. The scale was developed for the assessment of
non-randomized and observational studies, and assesses each
study based on three broad categories: selection of the study
groups or participants, the comparability of the groups, and the
ascertainment of either the exposure or outcome of interest.
Quality of studies was assessed and graded highest based on
specific parameters mentioned, and higher-quality studies were
accorded with higher points (8–10, good quality; 5–7 fair quality;
<5 low quality).
Data synthesis and analysis
Outcomes were grouped into four (4) major categories, namely: (a)
blood pressure (systolic blood pressure, diastolic blood pressure,
mean arterial pressure), (b) lipids (triglycerides, total cholesterol,
high-density lipoprotein [HDL], low-density lipoprotein [LDL], HDL/
LDL ratio, total cholesterol/HDL ratio), (c) markers of glucose
metabolism (serum glucose, insulin, Homeostatic Model Assess-
ment for Insulin Resistance [HOMA-IR]), and (d) inflammation
markers (Creactive protein (CRP and high-sensitivity CRP), tumor
necrosis factor-alpha and interleukin 6). All outcome measures
were expressed in conventional units. We computed pooled
means and standard deviation, and weighted mean difference
based on the extracted measurement from each study. We
combined the mean difference by weight using the random-
effects model developed by Der Simonian and Laird. In the
random-effects model, weighted means and mean difference
accounts for both the within-study and between-studies errors as
opposed to the usual computation of merely using errors (sample
size). Thus, we allow that the true effect estimate is within a
distribution rather than having one true effect estimate. Weighted
means were deemed appropriate as all our outcomes were
expressed in similar scales (Standardized mean difference would
be appropriate if different scales were used, which did not hold
true in our review). Heterogeneity was assessed using the
Cochrane χ² statistic and the I² statistic. Study characteristics
including patient characteristics (median age, median body mass
index, sex distribution, and baseline cardiovascular disease/
medications), injury characteristics (completeness of lesion and
duration of injury) and study characteristics (study location, the
median number of participants, and study quality) were pre-
specified as characteristics for assessment of heterogeneity and
were evaluated using stratified analyses and random-effects meta-
regression if eight or more studies were included in the meta-
analysis. In addition, we performed meta-regression to determine
the association between the age, percentage of the male
population, injury duration, completeness of injury, and body
mass index to each cardiovascular risk factor. To assess the impact
of each study in the analyses, a leave-one-out analysis was done
by iteratively estimating the weighted mean difference by
removing a study one at a time. Asymmetry was assessed by
Egger’s test, and publication bias was evaluated through a funnel
plot. All tests were performed by using two-tailed tests, with p <
0.05 as significant. All statistical analyses were conducted with
STATA, Release 16.1 (Stata Corp, College Station, Texas, USA). The




A total of 7411 relevant citations were identified on 5 databases
searched (Fig. 1). After removing duplicates, 4863 citations were
evaluated using titles and abstracts by two independent reviewers















for relevance. Three hundred ten (310) articles underwent full-text
review, and 11 additional articles were identified from cross-
reference. In total, 65 observational studies comprising 7342
individuals with SCI were included in the review, of which
47 studies contributed to the meta-analysis with 3878 participants
(3280 males, 526 females, 72 unknown sex). We were able to
meta-analyze unadjusted mean biomarker levels from 26 studies
on blood pressure, 25 on serum lipid profiles, 14 on markers of
glucose metabolism, and 7 on inflammation markers. The majority
of studies (n= 44, 93.6%) compared individuals with tetraplegia
and paraplegia, while 12 studies compared high- to low-
paraplegia (T6 as the level of discrimination). All studies were
performed in individuals with chronic SCI (median SCI duration
was 13.5 years, interquartile range 10.7–14.7 years) and among
relatively young study participants (median age was 39.3 years),
and 22 studies (46%) were conducted only in males. Thirty-eight
studies (38, 80%) were of small sample size (n < 100). Most of the
studies were done in the US and Canada (n= 26, 55%) and Europe
(n= 10, 21%), while eight studies were done in Asia and one in
Latin America (Brazil). Table 1 summarizes the characteristics of
the studies included in the meta-analysis, and detailed informa-
tion on study characteristics of all studies included in our review
can be found in the Appendix (Appendix Table A1). The results
and reasons for non-extraction of the other 18 studies (11 for
7,411 Potenally relevant citaons idenfied 
3,802 Embase 
1,597 Medline via Ovid 
1,313 Web of Science 
400 Google Scholar 
299 Cochrane Central 
  2,548 duplicates removed and 4,863 citaons were 
evaluated based on tles and abstract (based on inclusion 
and exclusion criteria) 
-256 arcles were EXCLUDED due to  
• 104, no spinal cord injury level 
• 67, no outcome of interest  
• 24, duplicates 
• 22, wrong comparison (able bodied or non-SCI)  
• 21. non-peer-reviewed arcle (editorial, 
commentaries, narrave review, protocols) 
• 17, wrong design (different exposure and 
classificaon, modeling study, validaon)  
• 1, animal study
Quantave analysis (Meta-analysis) 
47 Studies included 
• 26, blood pressure 
• 25, serum lipid profile 
• 14, glucose metabolism 
• 7, inflammatory markers 
























+11 arcles INCLUDED from cross-reference
Qualitave analysis  
18 Studies included 
• 8, blood pressure 
• 11, serum lipid profile 
• 7, glucose metabolism 
• 8, inflammatory markers
65 Studies included in systemac 
review 
Fig. 1 Flowchart of included studies in the systematic review.
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Table 1. Descriptive characteristics of studies included in the meta-analysis (n= 47).
Characteristic No. of studies References
Level of injury
Tetraplegia vs paraplegia 44 Aadriansen 2016, Akbal 2013, Apstein 1998, Baumann 1992, Baumann 1999, Brenes 1986, Buchholz
2009, Campbell 2004, Cardus 1992, Davies 2007, de Groot 2008, Farkas 2018, Frost 2005, Gibson 2008,
Gorgey 2010, Gorgey 2011, Grimm 1997, Heidebreder 1982, Houtmann 1999, Huang 2008, Janssen
1997, Katzelnick 2019, Kemp 2000, Kim 2016, King 1994, Kjaer 2001, Kooner 1988, Laclaustra 2014,
Legramante 2001, Matos Souza 2010, Miyatani 2014, O Brien 2017, Raymond 2010, Sabour 2013,
Schmid 2000, Schmid 2008, Wang 2007, Wecht 2001, Wecht 2006, Wong 2001, Yahiro 2019, Zhong
1995, Zhou 1997, Zhu 2013
High vs. low paraplegia 12 Aadriansen 2016, Bernardi 2019, Campbell 2004, Janssen 1997, Katzelnick 2017, Katzelnick 2019, Kim
2016, King 1994, Krum 1989, Raymond 2010, Sisto 2012, Zhu 2013
Proportion of complete SCI
≤63% (median) 15 Akbal 2013, Davies 2007, de Groot 2008, Gibson 2008, Grimm 1997, Huang 2008, Janssen 1997,
Katzelnick 2017, Katzelnick 2019, Laclaustra 2014, Miyatani 2014, Raymond 2010, Sabour 2013, Wecht
2001, Wecht 2006
>63% 15 Aadriansen 2016, Baumann 1999, Farkas 2018, Gorgey 2010, Gorgey 2011, Kemp 2000, Kooner 1988,
Legramante 2001, O Brien 2017, Schmid 2000, Schmid 2008, Wang 2007, Wong 2001, Yahiro 2019,
Zhou 1997
Duration of injury (years)
≤13.5 y (median) 20 Akbal 2013, Baumann 1999, Cardus 1992, Davies 2007, Frost 2005, Grimm 1997, Huang 2008,
Katzelnick 2017, Krum 1989, Matos Souza 2010
Miyatani 2014, O Brien 2017, Raymond 2010, Sabour 2013, Schmid 2000, Schmid 2008, Sisto 2012,
Wang 2007, Wecht 2001, Wecht 2006
>13.5 y 15 Aadriansen 2016, Baumann 1992, Buchholz 2009, Cardus 1992, de Groot 2008, Farkas 2018, Gibson
2008, Janssen 1997, Katzelnick 2019, Kemp 2000, Laclaustra 2014, Wong 2001, Yahiro 2019, Zhong
1995, Zhu 2013
Sex
Male only 22 Apstein 1998, Baumann 1992, Baumann 1999, Bernardi 2019, Campbell 2004, Cardus 1992, Frost 2005,
Gorgey 2010, Gorgey 2011, Grimm 1997 Houtmann 1999, Janssen 1997, Kooner 1988, Legramante
2001, Matos Souza 2010, Matos Suoza 2010, O Brien 2017, Schmid 2000, Wang 2007, Wecht 2001,
Wecht 2006, Yahiro 2019, Zhong 1995
Both sex 25 Aadriansen 2016, Brenes 1986, Buchholz 2009, Davies 2007, de Groot 2008, Farkas 2018, Gibson 2008,
Heidebreder 1982, Huang 2008, Katzelnick 2017, Katzelnick 2019, Kemp 2000, Kim 2016, King 1994,
Kjaer 2001, Krum 1989, Laclaustra 2014, Miyatani 2014, Raymond 2010, Sabour 2013, Schmid 2008,
Sisto 2012, Wong 2001, Zhou 1997, Zhu 2013
Study size
<50 21 Bernardi 2019, Campbell 2004, Farkas 2018, Frost 2005, Grimm 1997, Heidebreder 1982, Huang 2008,
Janssen 1997, Katzelnick 2017, Kim 2016, King 1994, Kjaer 2001, Kooner 1988, Krum 1989, Legramante
2001, Matos Souza 2010, O Brien 2017, Raymond 2010, Wecht 2001, Wecht 2006, Zhou 1997
50–100 16 Akbal 2013, Apstein 1998, Baumann 1992, Baumann 1999, Brenes 1986, Buchholz 2009, Cardus 1992,
Davies 2007, Gibson 2008, Gorgey 2011A, Gorgey 2011B, Miyatani 2014, Schmid 2000, Schmid 2008,
Wong 2001, Wang 2007
>100 10 Aadriansen 2016, de Groot 2008, Katzelnick 2019, Kemp 2000, Laclaustra 2014, Sabour 2013, Sisto
2012, Yahiro 2019, Zhong 1995, Zhu 2013
Age, years
≤39.3 y (median) 25 Akbal 2013, Baumann 1999, Bernardi 2019, Brenes 1986, Campbell 2004, Cardus 1992, Gorgey 2010,
Gorgey 2011, Grimm 1997, Huang 2008, Janssen 1997, Katzelnick 2017, Kim 2016, King 1994, Krum
1989, Legramante 2001, Matos Souza 2010, O Brien 2017, Raymond 2010, Sabour 2013, Schmid 2000,
Schmid 2008, Wang 2007, Wecht 2006, Zhou 1997
>39.3 y 20 Aadriansen 2016, Apstein 1998, Baumann 1992, Buchholz 2009, Cardus 1992, Davies 2007, de Groot
2008, Farkas 2018, Frost 2005, Gibson 2008, Katzelnick 2019, Kemp 2000, Laclaustra 2014, Miyatani
2014, Sisto 2012, Wecht 2001, Wong 2001, Yahiro 2019, Zhong 1995, Zhu 2013
BMI, kg/m2
≤24.9 (median) 17 Aadriansen 2016, Baumann 1999, Brenes 1986, de Groot 2008, Gorgey 2010, Gorgey 2011, Janssen
1997, Kim 2016, Matos Souza 2010, O Brien 2017, Raymond 2010, Sabour 2013, Schmid 2000, Schmid
2008, Wang 2007, Wecht 2006, Wong 2001
>24.9 14 Akbal 2013, Baumann 1992, Buchholz 2009, Farkas 2018, Gibson 2008, Grimm 1997, Katzelnick 2017,
Katzelnick 2019, Kemp 2000, Miyatani 2014, Wecht 2001, Yahiro 2019, Zhong 1995, Zhu 2013
Location
Europe 11 Aadriansen 2016, Bernardi 2019, de Groot 2008, Heidebreder 1982, Janssen 1997, Kjaer 2001, Kooner
1988, Legramante 2001, Schmid 2000, Schmid 2008, Laclaustra 2014
North America 26 Apstein 1998, Baumann 1992, Baumann 1999, Brenes 1986, Buchholz 2009, Cardus 1992, Davies 2007,
Farkas 2018, Frost 2005, Gibson 2008, Gorgey 2010, Gorgey 2011, Grimm 1997, Katzelnick 2017,
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serum lipids, 8 for inflammation markers, 7 markers for glucose
metabolism, and 8 for blood pressure) were qualitatively
described and summarized in the Appendix (Appendix Table A2).
We only report in the text the weighted mean difference (WMD)
for statistically significant values, otherwise, crude group mean
was provided.
Blood pressure
Based on the findings from 20 studies and 1516 individuals with SCI,
systolic and diastolic BP, and mean arterial pressures were lower in
tetraplegia in comparison to individuals with paraplegia with the
weighted mean difference (WMD) −14.5mmHg (95% CI −19.2, −9.9,
p< 0.001, I2 92.5%), −7.0mmHg (95% CI −9.2, −4.8, p< 0.001, I2
79.7%) and −15.2 mmHg (95% CI −25.0, −5.4, p< 0.001, I2 87.3%),
respectively (Table 2). In line with this, based on findings from
10 studies and 761 SCI individuals, individuals with high-paraplegia
had lower systolic and diastolic BP compared to low-paraplegia (at T5-
T6 and below) with WMD −10.3mmHg (95% CI −13.4, −7.1, p =
0.004, I2 62.8%) and −5.3mmHg (95% CI −7.5, −3.2, p = 0.021, I2
53.8%), respectively. Furthermore, we also grouped the studies based
on the position in which the blood pressure was measured. For both
the supine and seated positions, WMD of systolic and diastolic BP was
lower in tetraplegia compared to individuals with paraplegia and
were in line with the overall findings. For systolic BP, the WMD were
−12.4mmHg (95% CI −28.4, −3.7, p< 0.001, I2 93.0%) for supine and
−13.2mmHg (95% CI −18.8, −7.4, p< 0.001, I2 88.3%) for seated,
both lower in individuals with tetraplegia than paraplegia. For
diastolic BP, the WMD were −6.6mmHg (95% CI −12.9, −0.4, p =
0.023, I2 68.4%) for supine and −6.4mmHg (95% CI −9.6, −3.3, p<
0.001, I2 79.0%) for seated, which were both lower for individuals with
tetraplegia than paraplegia. (Table 2).
Serum lipids
We analyzed 22 studies with 1951 individuals with SCI reporting
differences in lipid profiles (Table 2). In general, serum lipids were
lower in tetraplegia compared to paraplegia. Serum triglycerides
and total cholesterol levels were lower in tetraplegia as compared
to paraplegia with WMD −10.9 mg/dL (95% CI −19.7, −2.1, p <
0.001, I2 93.2%) and −9.9 mg/dL (95% CI −14.5, −5.4, p < 0.001, I2
91.5%), respectively. High-density lipoprotein (HDL) and low-
density lipoprotein (LDL) was also lower in tetraplegia compared
to paraplegia (WMD −1.7 mg/dL, 95% CI −3.3, −0.2, p < 0.001, I2
95.8% and −5.8 mg/dL, 95% CI −9.0, −2.5 p < 0.001, I2 82.8%).
Results in the male-only population were in line with the overall
findings (Appendix Table A3-a). We found no significant
differences in HDL-LDL ratio and cholesterol-HDL ratio levels
among the two groups.
Glucose metabolism
Based on findings from 13 studies and 985 participants, mean
glucose levels in individuals with tetraplegia was 95.9 mg/dL ±
19.7 compared with paraplegia with 93.4 mg/dL ± 18.8, but pooled
estimates did not show a significant difference (WMD −0.5 mg/dL,
95% CI −1.9, 1.0, p = 0.084, I2 37.5%) (Table 2). The mean serum
insulin levels in individuals with tetraplegia were 9.8 uU/mL ± 5.4
compared to those with paraplegia 8.9 uU/mL ± 4.2, and the
pooled difference between the groups was not statistically
significant (WMD −0.3, 95% CI −1.8, 1.1, p < 0.001, I2 81.6%).
When comparing male-only WMD with mixed-population esti-
mates, we did not find statistically significant differences in
glucose and insulin levels between the two groups (tetraplegia
and paraplegia) (Appendix Table A3-a).
Inflammation and oxidative stress markers
Based on 4 studies and 199 individuals, the mean levels of high-
sensitivity C-reactive protein (hsCRP) in tetraplegia was 4.14 mg/L
± 3.91 compared to 3.93 mg/L ± 3.95 for individuals with para-
plegia. However, the WMD was not significantly different between
the two groups (0.56 mg/L, 95% CI −0.25, 1.37, p = 0.176, I2
39.4%). No differences were observed with interleukin 6 (4 studies,
199 individuals) and tumor necrosis factor-alpha (3 studies, 137
individuals) (Table 2) for different injury levels. Similarly, when
Table 1 continued
Characteristic No. of studies References
Katzelnick 2019, Kemp 2000, Kim 2016, King 1994, Miyatani 2014, O Brien 2017, Sisto 2012, Wecht
2001, Wecht 2006, Yahiro 2019, Zhong 1995, Zhu 2013
South America 1 Matos Souza 2010
Asia 9 Akbal 2013, Campbell 2004, Huang 2008, Krum 1989, Raymond 2010, Sabour 2013, Wang 2007, Wong
2001, Zhou 1997
Outcomes
Blood lipids 25 Akbal 2013, Apstein 1998, Baumann 1992, Bernardi 2019, Brenes 1986, Buchholz 2009, Cardus 1992,
de Groot 2008, Farkas 2018, Gibson 2008, Gorgey 2010, Gorgey 2011, Janssen 1997, Kemp 2000,
Lacluastra 2014, Matos Souza 2010, Miyatani 2014, O Brien 2017, Sabour 2013, Schmid 2000, Schmid
2008, Wang 2007, Wong, 2001, Yahiro 2019, Zhong 1995
Blood glucose 14 Akbal 2013, Baumann 1999, Buchholz 2009, Campbell 2004, Farkas 2018, Gibson 2008, Gorgey 2010,
Huang 2008, Matos Souza 2010, Miyatani 2014, O Brien 2017, Sabour 2013, Yahiro 2019, Wang 2007
Blood pressure 26 Aadriansen 2016, Akbal 2013, Buchholz 2009, Farkas 2018, Grimm 1997, Heidebreder 1982, Houtmann
1999, Janssen 1997, Katzelnick 2017, Katzelnick 2019, Kim 2016, King 1994, Kjaer 2001, Kooner 1988,
Krum 1989, Legramante 2001, Matos Souza 2010, Miyatani 2014, Raymond 2010, Sabour 2013, Sisto
2012, Wecht 2001, Wecht 2006, Yahiro 2019, Zhou 1997, Zhu 2013
Inflammation markers 7 Buchholz 2009, Davies 2007, Farkas 2018, Frost 2005, Gibson 2008, Huang 2008, Wang 2007
Study quality
Moderate (5–7) 6 Baumann 1992, Campbell 2004, Cardus 1992, Heidebreder 1982, Kooner 1988, Zhou 1997
Good (8–10) 41 Aadriansen 2016, Akbal 2013, Apstein 1998, Baumann 1999, Bernardi 2019, Brenes 1986, Buchholz
2009, Davies 2007, de Groot 2008, Farkas 2018, Frost 2005, Gibson 2008, Gorgey 2010, Gorgey 2011,
Grimm 1997, Huang 2008, Janssen 1997, Katzelnick 2017, Katzelnick 2019, Kemp 2000, Kim 2016, King
1994, Kjaer 2001, Krum 1989, Laclaustra 2014, Legramante 2001, Matos Souza 2010, Miyatani 2014, O
Brien 2017, Raymond 2010, Sabour 2013, Schmid 2000, Schmid 2008, Sisto 2012, Wang 2007, Wecht
2001, Wecht 2006, Wong 2001, Yahiro 2019, Zhong 1995, Zhu 2013
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comparing male-only WMD with mixed-population estimates, we
did not find statistically significant differences in CRP levels
between the two groups (tetraplegia and paraplegia) (Appendix
Table A3-a).
Sensitivity analyses and assessments of bias, study quality
and heterogeneity
The quality of the majority (87%) of observational studies included
in meta-analyses was judged to be of good quality (Newcastle-
Ottawa Scale score ranged from 8 to 10) (Appendix Table A1). In
general, meta-analyses showed high between-study heterogene-
ity, with an I2 estimate exceeding 75% (p < 0.05 for the Cochrane
χ2 statistic) (Appendix Fig. A1). The heterogeneity of the outcomes
was barely explained by the meta-regression analysis. However,
factors such as age, body mass index (BMI), prevalent CVD, lesion
duration, sample size, and study quality are suggested to be the
sources of heterogeneity across different outcomes (Appendix
Table A3a & b). BMI was seen as source of heterogeneity for HDL.
Baseline cardiovascular disease and the use of cardiovascular
medications were also documented. However, except for an
indication that this may be a source of heterogeneity in meta-
analysis focusing on triglycerides and HDL, no significant
differences were observed across the risk factors. We also used
meta-regression to fit a regression line on patient characteristics
and the cardiovascular risk factors (Appendix Table A4). BMI
seemed to affect the disparity of insulin between individuals with
tetraplegia and paraplegia. The disparity in insulin increased with
increasing BMI (β 0.94, 95% CI 0.29, 1.60). Age influenced HDL
(β 0.18, 95% CI 0.01, 0.35) Duration of injury also influenced HDL
and insulin levels, as both increase together with longer duration
of injury (β 0.37, 95% CI 0.08, 0.66, and 1.02, 95% CI 0.07, 1.98,
respectively) (Appendix Table A4).
Leave-one-out analyses were done to determine if one study
was driving the overall effect estimate (Appendix Fig. A2). The
removal of the study of Wang et al. [20] changed the pooled
estimate, so that individuals with tetraplegia had higher insulin
levels compared to paraplegia (WMD 0.74 uU/mL, 95% CI 0.24,
1.23). This study included those with infections which was not
done in other studies assessing insulin levels. By removing the
study of O’Brien, et al. [21], the estimates were also changed with
tetraplegia having a lower cholesterol-HDL ratio compared to
paraplegia (WMD −0.5, 95% CI −0.64, −0.35). Tests for publication
bias showed mostly symmetric distribution in funnel plots
(Appendix Fig. A3), except for HOMA-IR (Egger’s test p = 0.019),
cholesterol HDL ratio (Egger’s test p = 0.025), and HDL (Egger’s
test p = 0.102).
DISCUSSION
In this systematic review, a higher injury level (tetraplegia) was
associated with lower BP (systolic BP, diastolic BP, mean arterial
pressure MAP) compared to a lower injury level (paraplegia). A
higher injury level was associated with lower HDL in lipid profile,
albeit with lower triglycerides, total cholesterol, and LDL. We
found no differences in glucose metabolism and inflammation
markers. As some literature suggests higher CVD incidence in SCI
individuals with tetraplegia compared to paraplegia, our study
determined an exact difference between the two groups
according to their modifiable risk factors (eg., blood pressure
and serum lipids). Our results, however, were based mostly on
relatively young individuals, male population, chronic SCI, and
studies conducted in Europe and North America. Thus, our
findings may not be generalizable to all individuals with SCI. An
illustrative summary of the most critical findings and literature
gaps is provided in Fig. 2.
To the best of our knowledge, this is the first systematic review
that specifically focuses on the level of injury (as well as its
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two systematic reviews which primarily compared the BP and
blood lipids between individuals with SCI and ABI. Their respective
subgroup analyses, comparing across injury levels, were similar to
our findings. In the meta-analysis of West et al. including
21 studies, authors reported lower BP and heart rate values in
SCI individuals with a higher (cervical) compared to lower injury
level (high thoracic T1-T5 and low thoracic T6 below) [17]. In
another meta-analysis by Gilbert et al., total cholesterol and non-
HDL cholesterol were significantly lower in the tetraplegia
subgroup, while LDL and triglycerides were not different among
individuals with tetraplegia and paraplegia [16]. Our review
included more studies, contains more up-to-date articles, provided
male-specific analyses, and included more cardiovascular risk
factors. In addition, we used newer meta-analysis methods such as
stratification analysis and meta-regression to explore the role of
other factors that may mediate the association between injury
level and CVD risk factors such as individual study (e.g., number of
study participants, study location) and study participants char-
acteristics (e.g., percentage of males, age) and characteristics of
the injury (completeness and injury duration).
In SCI, the impairment ranges from the motor to neurohormo-
nal control below the level of injury. The autonomics play a crucial
role in the neurologic and hormonal control of the vascular tone. It
also plays a role in the homeostatic control of fluids, electrolytes,
glucose, and lipid metabolism [22]. The motor system is crucial in
controlling the movement of limbs and the spine (appendicular
and axial muscles), which determines an individual’s mobility and
physical activity. Thus, there could be a lesion-level-dependent
difference in CVD risk in the SCI population mediated via altered
autonomic function, metabolism, and physical activity levels [23].
Indeed, in a retrospective cohort study, the risk of clinically
apparent CVD was the highest in individuals with tetraplegia and
individuals with complete SCI as compared to other injury
modalities [24]. Similarly, atherosclerosis burden was different
according to injury level, carotid intima media thickness was
higher in tetraplegic subjects in comparison to paraplegic ones,
and individuals with tetraplegia and complete SCI had the highest
prevalence of silent coronary artery disease and a greater
prevalence of severe coronary artery calcification scores than
those with paraplegia [25–27].
Here we discuss potential mechanisms underlying the differ-
ences in cardiovascular risk factors observed in current systematic
reviews. The involvement of the autonomic nervous system was
suggested as the major mechanism in the blood pressure
differences across different injury levels. The autonomics play a
crucial function in the neurologic and hormonal control of the
vascular tone and can also play a role in the endocrine control of
fluids and electrolytes critical to BP control. In particular,
autonomic dysreflexia (usually present in individuals with damage
at or above T6 spinal segment) may mediate increased CVD risk in
individuals with tetraplegia compared to paraplegia via structural
and functional modifications to peripheral and cerebral vascula-
tures (due to repeated episodes of vascular contractions and
associated hypertension which occasionally can reach extreme
levels) [28]. Thus, considering that in the current study we were
not able to control for the diagnosis of autonomic dysreflexia, our
findings on lower systolic and diastolic BP and MAP observed in
tetraplegic individuals should be interpreted with caution (e.g., in
Fig. 2 Illustrative summary of the most important findings and literature gaps. (*in meta-regression analysis this factor was not indicated as a
source of heterogeneity; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, c-reactive protein; IL-6, interleukin 6; TNF-alpha,
tumor necrosis factor alpha; HOMA-IR, homeostatic model assessment for insulin resistance).
P.F. Raguindin et al.
8
Spinal Cord
individuals with SCI, the association between the BP values and
long-term cardiovascular disease risk may not follow the same
trend as compared to the ABI).
In addition to lower HDL in individuals with tetraplegia as
compared to paraplegia, we reported lower total cholesterol, LDL,
and triglycerides levels in the former group. In the subgroup
analyses exploring the lipid levels according to the different levels
of injury, two reviews had contradictory findings. Wilt et al. did not
find any significant difference [12], while Gilbert et al. reported
lower cholesterol and HDL in individuals with tetraplegia [16].
Exercise or involvement in physical activity may increase HDL
levels and improve its antioxidative and anti-inflammatory
properties, which may explain higher levels in individuals with
paraplegia who are able to exercise with full use of upper limbs
and the trunk, and thus are more physically active as compared to
tetraplegic individuals [29]. In addition, the majority of studies did
not provide information on statin use (which are mainly
prescribed due to their LDL-lowering properties), and therefore,
we cannot speculate whether lower total cholesterol, triglycerides,
and LDL levels seen in individuals with tetraplegia may be affected
by perhaps higher prevalence of statin-use in this group. Also,
some authors suggest that the lipid ratios (HDL-LDL ratio and
cholesterol-HDL) ratio may be a more important determinant of
increased CVD risk in individuals with SCI considering all the
physiological changes after injury [16]. In previous systematic
review, they observed that individuals with SCI have a higher
cholesterol HDL ratio than ABI, thus, the authors speculated that
the former have poorer cardiovascular profile than the latter [16].
In our review, in six out of nine studies we observed higher
cholesterol-HDL ratio in tetraplegia (poorer lipid profile). Still,
pooled estimates did not show statistically significant differences,
which might be attributed to limited number of studies included in
analyses or the heterogeneity among available studies.
Furthermore, we found no differences between the two groups
in glucose metabolism and inflammation parameters. The
determinants of glucose metabolism have been proven to be
more complex. In a large study on glucose metabolism, individuals
with tetraplegia had poorer glucose and insulin profiles than
paraplegia (after oral glucose tolerance test) [30]. In contrast,
studies comparing fasting blood glucose according to injury level
reported no differences [20, 31, 32]. Conflicting findings could be a
consequence of methodological differences between the studies
and the fact that fasting blood glucose may be less sensitive than
oral glucose tolerance tests in detecting hyperglycemia. Also,
other mitigating factors such as baseline inflammation [33] and
physical activity [34] may play important roles in glucose control,
however, studies have only compared the mean differences
between the groups without considering these confounding
factors. In fact, there is a general trend of higher inflammation
markers in SCI individuals, which is a consequence of chronic
urinary tract infection, skin ulcers, and reduced physical activity,
among others [20, 35, 36]. Limited evidence also suggests higher
inflammation status in tetraplegia compared to paraplegia.
However, the studies had small sample sizes, and several
confounding factors were not considered. As such, the influence
of the level of injury is still poorly described. Similar to glucose
metabolism, the complex interaction of neurohormonal control
and physical activity through the motor pathway could determine
the inflammation marker levels.
In addition to the injury level, the completeness of the injury
and its duration are also important contributing factors that can
affect cardiovascular risk factors. As seen in our subgroup analyses,
the completeness and injury duration were additional injury-
related factors that could possibly mediate the CVD risk but needs
further research to be proven. Completeness of injury is usually
assessed using the ASIA impairment scale. This scale, however,
fails to consider the autonomic function. And as such, reviews
have not fully elucidated its influence on blood pressure and
lipids. As for the duration of injury, factor analysis has been
challenging as age is highly correlated with injury duration (36,
37). A longitudinal study has shown that quality of life, activity,
and participation declines with the duration of injury, along with
age and age of onset (38).
Strengths and limitations
Studies in SCI frequently lack statistical power due to small sample
sizes. This is primarily due to the low incidence of SCI, few
registries that collect standardized information on SCI, and few
collaborative studies across different rehabilitation centers [37].
Therefore, combining studies using meta-analysis may solve this
issue. To our knowledge, this is the largest meta-analysis focusing
on the level of SCI and cardiovascular disease risk factors. To
identify as many relevant studies as possible and reduce the risk of
publication bias, a highly sensitive search strategy was used, and
additional resources were searched, including the reference list of
included studies and relevant systematic reviews. We also
included studies that did not include CVD as a primary outcome
but provided information on CVD risk factors to include more
individuals in our pooled estimate.
However, we report some weaknesses that need to be
considered when interpreting our data. First, although the studies
included were of good quality, these were observational studies
and provided unadjusted mean biomarker levels, precluding our
ability to speculate on causality. Second, there were crucial gaps in
the reporting of other critical cardiovascular risk factors in most
studies. Most studies did not report smoking history and
medication use. Physical activity, diet, and other lifestyle factors
were also seldomly reported. Third, we did not identify any study
exploring the association between injury level and markers of
endothelial/vascular function and carotid atherosclerosis, which
would have strengthened our findings. Fourth, some studies have
used similar study participants, which may result in double
reporting. We solved this problem by comparing the study
characteristics and including the latest publication only or the
study with the most relevant outcome of interest. Finally, females
were grossly underrepresented in our analysis (526/3878 or
13.5%), thus, our analysis could only be generalized to males.
Despite sex is a critical determinant of cardiovascular risk, the SCI
researches rarely included females or performed female-specific
analyses and we discussed this phenomenon elsewhere [38].
Research gaps and implications for future research
Although SCI individuals are considered to have increased
cardiovascular risk, the number of SCI-specific clinical guidelines is
limited, and validated CVD risk prediction models for SCI are lacking
[39]. Understanding how the injury contributes to the overall
cardiovascular risk in SCI individuals is crucial in tailoring the
preventive strategies in this high-risk population. The risk prediction
models used in ABI (e.g., FRS) may not be valid estimators of future
cardiovascular events in SCI individuals. The results of the current
meta-analysis suggest that the anatomic level of the injury may be a
critical non-modifiable CVD risk factor for this population. Sufficiently
powered longitudinal studies should be done to establish causality.
Future studies should also include individuals in subacute SCI and
include both males and females to allow sex-specific analyses. These
subsequent studies would improve our understanding of the role of
the injury level in modifying CVD risk and whether the injury level
may be used for risk stratification and development of injury-specific
prevention and treatment strategies.
CONCLUSION
Our findings suggest that the injury level may be an additional
non-modifiable cardiovascular risk factor for individuals with SCI. In
SCI individuals with a higher injury level, blood pressure was lower
compared to lower injury. In regards to lipids, individuals with
P.F. Raguindin et al.
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higher injury levels have lower HDL, albeit with lower cholesterol,
triglycerides, and LDL. We found no differences in glucose
metabolism and inflammation markers. Factors such as age,
prevalent CVD and medication use, BMI, sample size, and quality
of studies may be important factors that affect our estimates and
could have precluded our ability to detect differences in glucose
metabolism parameters. To better understand the role of injury
level in modifying CVD risk and confirm our findings, future
longitudinal studies should be sufficiently powered and include
individuals with subacute and chronic SCI, including both males
and females, to allow for sex-specific analysis.
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